Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2001

View Archived Issues

Licensing opportunity from NIH: mutations applicable for development of dengue vaccines

DPC-602 exerts antithrombotic effects in animals at doses not causing bleeding

Direct-acting factor Xa inhibitor PD-198961 shows promise for both arterial and venous thrombosis

Factor Xa-selective anticoagulant DPC-423 has oral bioavailability and antithrombotic activity

CI-1031 may have a more favorable therapeutic index than enoxaparin

Prolonged inhibition of factor Xa with SanOrg-34006 provides high patency rate after thrombolysis

Acquisition of Aurora by Vertex cleared by FTC

Agouron returns Remune rights to Immune Response

Mixed thrombin, factor Xa and platelet aggregation inhibition provided by BIBR-830ZW

Metabolex begins phase I trials of MBX-102

FDA grants orphan drug status to Avigen's Coagulin-B

Ixense/Uprima launched in Germany, France and Spain for treatment of ED

ISTH news: promising new factor VIIa inhibitor synthesized at Ajinomoto

Role for olanzapine in Alzheimer's disease patients with BPSD

Xenova receives FDA approval to resume clinical trials with anticocaine addiction vaccine

Pharmacological profile of dual TxA2 antagonist and Tx synthase inhibitor discussed at ISTH

NCX-4016 has distinct pharmacological properties from acetylsalicylic acid

First nonpeptide protease inhibitor effective in patients failing PI-containing regimens

Alteon begins SAPPHIRE trial of ALT-711 for treatment of isolated systolic hypertension

Tricyclic PCOs reported by Abbott, particularly useful in bladder disorders

Lilly patents new thrombin inhibitors with improved PK profile

Imidazole-based PDE and TNF-alpha production inhibitors identified at Merck

Potential treatments for angiogenic disorders claimed by GSK company

New thiazolidinediones under evaluation by Vita-Invest

Preparation, activity and use of new series of GlyT-1 inhibitors

Boehringer Ingelheim discovers new tryptase inhibitors

Nociceptin receptor ligands discovered at Novo Nordisk to be useful against hot flashes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...